Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
PARP inhibitors are a promising alternative to chemotherapy for patients with metastatic BRCA1 and BRCA2 breast cancer

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.06.19
Views: 2603

Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA

Dr Sara A. Hurvitz talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the use of PARP inhibitors in patients with metastatic BRCA1 and BRCA2 breast cancer and how they offer a promising alternative to chemotherapy.

She explains that for patients with BRCA 1, who often have triple negative disease, these drugs offer an alternative to chemotherapy which expands the time they can live with their disease controlled.

Dr Hurvitz also explains that while the use of PARP inhibitors hasn't been well studied in patients with other deleterious germline mutations there are ongoing trials looking at whether PARP inhibitors or PARP inhibitors in combination with other therapies may improve outcomes.

This programme has been supported by an unrestricted educational grant from Pfizer.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation